Skip to main content
SpringerLink
Log in

Prediction of tumor recurrence after radical prostatectomy using elimination kinetics of prostate-specific antigen

  • Published:
World Journal of Urology Aims and scope Submit manuscript

Summary

The serum half-life of prostate-specific antigen (PSA) calculated subsequent to radical prostatectomy can serve to predict which patients are at high risk of bearing residual prostatic carcinoma despite their initial attainment of undetectable PSA serum levels. This report updates previous results to a mean follow-up period of 37 months. The initial results are essentially confirmed in that a mean PSA elimination half-life of 1.6 days in patients considered to be cured at least 24 months after prostatectomy provides additional useful information for predicting outcome in patients with potentially curable prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Allhoff E, Riese W de, Eifinger M, Pethke J, Jonas U (1989) Prostate-specific antigen — comparative clinical appreciation of a serodiagnostic measure after 8 years of experience. World J Urol 7:12–16

    Google Scholar 

  2. Foster LS, Shinohara K, Carroll PR, Tanagho EA, Narayan P (1991) Residual prostate tissue as a cause for elevated PSA following radical prostatectomy. J Urol 145 [Suppl 4]:216A

  3. Gleave ME, Hsieh JT, Wu HC, Eschenbach AC von, Chung LWK (1992) Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res 52:1598–1605

    Google Scholar 

  4. Hudson MA, Bahnson RR, Catalona WJ (1989) Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 142:1011–1017

    Google Scholar 

  5. Kleer E, Larson-Keller JJ, Zincke H, Oesterling JE (1993) Ability of preoperative serum prostate-specific antigen value to predict pathologic stage and DNA ploidy. Urology 41:207–216

    Google Scholar 

  6. Lange PH, Ercole CJ, Lightner DJ, Fraley EE, Vessella R (1989) The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 141:873–879

    Google Scholar 

  7. Lightner DJ, Lange PH, Reddy PK, Moore L (1990) Prostate specific antigen and local recurrence after radical prostatectomy. J Urol 144:921–926

    Google Scholar 

  8. Oesterling JE, Chan DW, Epstein JI, Kimball AW, Bruzek DJ, Rock RC, Brendler CB, Walsh PC (1988) Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 139:766–772

    Google Scholar 

  9. Oesterling JE, Andrews PE, Suman VJ, Zincke H, Myers RP (1993) Preoperative androgen deprivation therapy: artificial lowering of serum prostate specific antigen without downstaging the tumor. J Urol 149:779–782

    Google Scholar 

  10. Oesterling JE (1991) Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145:907–923

    Google Scholar 

  11. Pontes JE, Foemmel R, Jabalameli P, Howard PD, Montie J, Boyett J (1990) Prognostic implications of disappearance rate of biologic markers following radical prostatectomy. Urology 36:415–419

    Google Scholar 

  12. Schifman RB (1993) Prostate-specific antigen half-life. Lab Med Abstr Commun 3:2–3

    Google Scholar 

  13. Schifman RB, Ahmann FR, Elvick A, Ahmann M, Coulis K, Brawer MK (1987) Analytical and physiological characteristics of prostate-specific antigen and prostatic acid phosphatase in serum compared. Clin Chem 33:2086–2088

    Google Scholar 

  14. Schmid HP, McNeal JE, Stamey TA (1993) Observations on the doubling time of prostate cancer. Cancer 71:2031–2040

    Google Scholar 

  15. Semjonow A, Hamm M, Rathert P (1992) Half-life of prostate-specific antigen after radical prostatectomy: the decisive predictor of curative treatment? Eur Urol 21:200–205

    Google Scholar 

  16. Stamey TA, Yang N, Hay AR, McNeal JE, Feiha FS, Redwine E (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317:909–916

    Google Scholar 

  17. Stamey TA, Kabalin JN, McNeal JE, Johnstone IM, Freiha F, Redwine EA, Yang N (1989) Prostatic specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 141:1076–1083

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Münster, Albert-Schweitzer-Strasse 33, D-48149, Münster, Germany

    A. Semjonow

  2. Department of Urology, Düren Academic Hospital, Technical University of Aachen, Roonstrasse 30, D-5235, Düren, Germany

    M. Hamm & P. Rathert

Authors
  1. A. Semjonow
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Hamm
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Rathert
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Semjonow, A., Hamm, M. & Rathert, P. Prediction of tumor recurrence after radical prostatectomy using elimination kinetics of prostate-specific antigen. World J Urol 11, 218–220 (1993). https://doi.org/10.1007/BF00185073

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00185073

Keywords

Search

Navigation